Solvonis Therapeutics PLC (LSE:SVNS, FRA:J4I) says new preclinical data show its lead drug matches fluoxetine (Prozac) in depression models. The drug targets serotonin and dopamine, aiming to help patients who don’t fully respond to current antidepressants. Watch more
hVIVO PLC (AIM:HVO) expects full-year revenue around £46.7 million, with margins beating expectations after a strong Q4. The company says recent acquisitions mean it’s now a full-service early-stage drug development group. Watch more
OptiBiotix Health PLC (AIM:OPTI, OTCQB:OPTBF) is seeing strong demand for its SlimBiome weight management ingredient, especially in the US. Management says growth is driven by consumers looking for alternatives to drugs like Ozempic. Watch more
Genflow Biosciences Ltd (LSE:GENF, OTCQB:GENFF, FRA:WQ5) has secured a €4 million non-dilutive grant to push key programmes. Focus is on its MASH gene therapy and a first-of-its-kind longevity study in ageing dogs. Watch more
Valereum PLC (AQSE:VLRM, FRA:6JT) has added $200 million to its balance sheet after completing a major transaction. The company says several tokenisation and markets infrastructure deals are moving closer to launch. Watch more
Tooru PLC (AIM:TOO, FRA:73N) says momentum is building after its AIM listing and business consolidation. Brands like OAF are gaining traction in Tesco, with management eyeing wider retail and overseas expansion. Watch more
Follow us and subscribe on YouTube, our social channels and on proactiveinvestors.co.uk.
